OABI
BEARISH
$1.48
Live
OmniAb, Inc. · NASDAQ
Target $7.33
(+395.5%)
$1.22
52W Range
$2.29
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$214.28M
P/E
N/A
ROE
-23.4%
Profit margin
N/A
Debt/Equity
0.08
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
OABI presents a contradictory profile: while the Piotroski F-Score of 6/9 indicates stable financial health and the balance sheet is strong with low debt and high liquidity, the operational data is alarming. Revenue is declining sharply (-22.5% YoY), and the stock is in a severe technical downtrend with bearish insider activity from the CEO and CFO. Despite a 'Strong Buy' analyst consensus and a high price target, the fundamental divergence between shrinking top-line growth and high Price/Sales valuation suggests significant risk.
Key Strengths
Strong liquidity with a Current Ratio of 4.02
Very low leverage (Debt/Equity of 0.08)
Exceptional Gross Margins (98.38%)
Trading below book value (Price/Book 0.80)
Stable Piotroski F-Score (6/9)
Key Risks
Significant revenue contraction (-22.5% YoY)
Severe operating losses (Operating Margin -147.35%)
Strong bearish insider selling by key executives
Consistent failure to meet earnings estimates (1/4 beats in last year)
Persistent negative price momentum across all timeframes
AI Fair Value Estimate
Based on comprehensive analysis
$2.1
+41.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
40
20
15
75
0
AI Verdict
High Risk / Speculative
Key drivers: Revenue decline, Insider selling, Technical breakdown, Strong balance sheet
Confidence
85%
Value
40/100
Graham Number N/A due to negative earnings; valuation is purely asset-based or speculative.
Positives
- P/B ratio of 0.80 suggests the stock is cheap relative to assets
Watchpoints
- High P/S ratio (11.48) for a company with shrinking revenue
- Negative Forward P/E
Future
20/100
Growth metrics are currently trending downward, contradicting analyst optimism.
Positives
- Analyst target price of $7.33 suggests massive potential upside
Watchpoints
- Negative YoY and Q/Q revenue growth
- Negative operating margins
Past
15/100
Long-term historical performance is extremely poor.
Positives
- Recent slight improvement in EPS growth
Watchpoints
- 5-year price collapse of -84.8%
- Consistent earnings misses
Health
75/100
The company is financially solvent and well-capitalized despite operational failures.
Positives
- Piotroski F-Score of 6/9
- Low Debt/Equity
- High Quick Ratio (3.78)
Watchpoints
- Negative ROE and ROA
Dividend
0/100
Typical for early-stage/struggling biotech.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.48
Analyst Target
$7.33
Upside/Downside
+395.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OABI and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OABI
OmniAb, Inc.
Primary
|
-84.8% | -59.8% | -21.7% | -13.4% | -19.1% | -2.6% |
|
MENS
Jyong Biotech Ltd.
Peer
|
-72.4% | -72.4% | -72.4% | -95.0% | +40.9% | +13.0% |
|
LUCD
Lucid Diagnostics Inc.
Peer
|
-89.1% | -5.9% | +7.6% | +8.5% | -6.6% | +13.3% |
|
PRQR
ProQR Therapeutics N.V.
Peer
|
-66.2% | -8.3% | +74.6% | -28.4% | +15.7% | +7.6% |
|
OGI
Organigram Global Inc.
Peer
|
-84.9% | -32.0% | +46.1% | -22.4% | +7.0% | +9.3% |
OAB
OmniAb, Inc.
Primary
5Y
-84.8%
3Y
-59.8%
1Y
-21.7%
6M
-13.4%
1M
-19.1%
1W
-2.6%
MEN
Jyong Biotech Ltd.
Peer
5Y
-72.4%
3Y
-72.4%
1Y
-72.4%
6M
-95.0%
1M
+40.9%
1W
+13.0%
LUC
Lucid Diagnostics Inc.
Peer
5Y
-89.1%
3Y
-5.9%
1Y
+7.6%
6M
+8.5%
1M
-6.6%
1W
+13.3%
PRQ
ProQR Therapeutics N.V.
Peer
5Y
-66.2%
3Y
-8.3%
1Y
+74.6%
6M
-28.4%
1M
+15.7%
1W
+7.6%
OGI
Organigram Global Inc.
Peer
5Y
-84.9%
3Y
-32.0%
1Y
+46.1%
6M
-22.4%
1M
+7.0%
1W
+9.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.93
PEG Ratio
N/A
P/B Ratio
0.8
P/S Ratio
11.48
EV/Revenue
9.52
EV/EBITDA
-3.79
Market Cap
$214.28M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-147.35%
Gross Margin
98.38%
ROE
-23.36%
ROA
-13.04%
Growth
Revenue and earnings growth rates
Revenue Growth
-22.5%
Earnings Growth
N/A
Q/Q Revenue Growth
-22.47%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.08
Low debt
Current Ratio
4.02
Strong
Quick Ratio
3.78
Excellent
Cash/Share
$0.37
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
99.9%
Op. Margin
-188.2%
Net Margin
-169.3%
Total Assets
$0.3B
Liabilities
$0.0B
Equity
$0.3B
Debt/Equity
0.13x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-04
$-0.11
-25.7% surprise
2025-11-04
$-0.14
-2.9% surprise
2025-08-06
$-0.15
+1.1% surprise
Healthcare Sector Comparison
Comparing OABI against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-23.36%
This Stock
vs
-100.15%
Sector Avg
-76.7%
(Below Avg)
Debt to Equity
0.08
This Stock
vs
3.22
Sector Avg
-97.6%
(Less Debt)
Revenue Growth
-22.5%
This Stock
vs
121.05%
Sector Avg
-118.6%
(Slower)
Current Ratio
4.02
This Stock
vs
4.55
Sector Avg
-11.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OABI
OmniAb, Inc.
|
BEARISH | $214.28M | - | -23.4% | -% | $1.48 | |
|
MENS
Jyong Biotech Ltd.
|
BEARISH | $212.12M | - | -% | -% | $2.79 | Compare |
|
LUCD
Lucid Diagnostics Inc.
|
BEARISH | $218.06M | - | -710.6% | -% | $1.28 | Compare |
|
PRQR
ProQR Therapeutics N.V.
|
BEARISH | $209.67M | - | -61.2% | -258.1% | $1.99 | Compare |
|
OGI
Organigram Global Inc.
|
BEARISH | $209.6M | 13.82 | 4.6% | 6.5% | $1.52 | Compare |
OABI
OmniAb, Inc.
BEARISH
Mkt Cap
$214M
P/E
-
ROE
-23.4%
Price
$1.48
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | FOEHR MATTHEW W | Chief Executive Officer | Sale | 19,244 | $28,674 |
| 2026-04-07 | FOEHR MATTHEW W | Chief Executive Officer | Stock Award | 36,459 | - |
| 2026-04-07 | BERKMAN CHARLES S | Officer | Sale | 7,157 | $10,664 |
| 2026-04-07 | BERKMAN CHARLES S | Officer | Stock Award | 13,542 | - |
| 2026-04-07 | GUSTAFSON KURT A | Chief Financial Officer | Sale | 6,913 | $10,300 |
| 2026-04-07 | GUSTAFSON KURT A | Chief Financial Officer | Stock Award | 13,542 | - |
| 2026-02-18 | FOEHR MATTHEW W | Chief Executive Officer | Sale | 30,843 | $52,742 |
| 2026-02-18 | FOEHR MATTHEW W | Chief Executive Officer | Stock Award | 58,333 | - |
| 2026-02-18 | BERKMAN CHARLES S | Officer | Sale | 9,673 | $16,541 |
| 2026-02-18 | BERKMAN CHARLES S | Officer | Stock Award | 18,750 | - |
| 2026-02-18 | GUSTAFSON KURT A | Chief Financial Officer | Sale | 9,301 | $15,905 |
| 2026-02-18 | GUSTAFSON KURT A | Chief Financial Officer | Stock Award | 18,750 | - |
| 2026-02-17 | FOEHR MATTHEW W | Chief Executive Officer | Sale | 20,754 | $35,282 |
| 2026-02-17 | BERKMAN CHARLES S | Officer | Sale | 6,990 | $11,883 |
| 2026-02-17 | GUSTAFSON KURT A | Chief Financial Officer | Sale | 6,828 | $11,608 |
FOEHR MATTHEW W
Chief Executive Officer
2026-04-07
19,244 shares
·
$28,674
FOEHR MATTHEW W
Chief Executive Officer
2026-04-07
36,459 shares
BERKMAN CHARLES S
Officer
2026-04-07
7,157 shares
·
$10,664
BERKMAN CHARLES S
Officer
2026-04-07
13,542 shares
GUSTAFSON KURT A
Chief Financial Officer
2026-04-07
6,913 shares
·
$10,300
GUSTAFSON KURT A
Chief Financial Officer
2026-04-07
13,542 shares
FOEHR MATTHEW W
Chief Executive Officer
2026-02-18
30,843 shares
·
$52,742
FOEHR MATTHEW W
Chief Executive Officer
2026-02-18
58,333 shares
BERKMAN CHARLES S
Officer
2026-02-18
9,673 shares
·
$16,541
BERKMAN CHARLES S
Officer
2026-02-18
18,750 shares
GUSTAFSON KURT A
Chief Financial Officer
2026-02-18
9,301 shares
·
$15,905
GUSTAFSON KURT A
Chief Financial Officer
2026-02-18
18,750 shares
FOEHR MATTHEW W
Chief Executive Officer
2026-02-17
20,754 shares
·
$35,282
BERKMAN CHARLES S
Officer
2026-02-17
6,990 shares
·
$11,883
GUSTAFSON KURT A
Chief Financial Officer
2026-02-17
6,828 shares
·
$11,608
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning OABI from our newsroom.
Newest → oldest
No matching news yet.